Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportGeneral Clinical Specialties

Management of cancer thyroid: Is there a role for carbimazole?

Hussein Farghaly, Waleed Diab, Lamia Mahmoud, Hemat Mahmoud, Nahla Bashank and Asmaa Mohamed
Journal of Nuclear Medicine May 2014, 55 (supplement 1) 480;
Hussein Farghaly
1Clinical Oncology-Nuclear Medicine Unit, Assiut University, Assiut, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Waleed Diab
1Clinical Oncology-Nuclear Medicine Unit, Assiut University, Assiut, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lamia Mahmoud
1Clinical Oncology-Nuclear Medicine Unit, Assiut University, Assiut, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hemat Mahmoud
1Clinical Oncology-Nuclear Medicine Unit, Assiut University, Assiut, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nahla Bashank
1Clinical Oncology-Nuclear Medicine Unit, Assiut University, Assiut, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asmaa Mohamed
1Clinical Oncology-Nuclear Medicine Unit, Assiut University, Assiut, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

480

Objectives Thyroglobulin (Tg) levels and the uptake of 131I (RAIU)on a whole body scan (WBS) in follow-up of differentiated thyroid carcinoma (DTC) depend on TSH stimulation, which in thyroidectomized patients (pts) can be obtained either by withdrawal of thyroxine (T4) or by administration of recombinant human TSH (rhTSH). As rhTSH is expensive and not available in our hospital we investigated whether carbimazole can be used to increase TSH level in pts with DTC with low TSH inspite of T4 withdrawal.

Methods It is a prospective study included 15 DTC pts with TSH failed to rise to >30 mIU/L at the time of I-131 WBS due to large residual seen in U/S or functioning metastasis and surgery cannot be done. All pts had low TSH less than 30 mIU/ after T4 withdrawal for 4 w. All pts received 2 tablets Carbimazole 5 mg 2x3 daily for 2 w and then check TSH level, if it is >30 mIU/L proceed for I-131 WBS if not continue with higher Carbimazole dose (3x3) for 1 or 2 more w and then check TSH. We reviewed the I-131 WBS of those pts with successful elevation of TSH to assess RAIU. The end point of this is TSH level is >30 mIU/L or maximum 4 w of Carbimazole intake. Paired samples t-test used to compare between TSH levels before and after Carbimazole.

Results TSH elevated to >30 mIU/L in 7 pts received 2x3 Carbimazole for 2 w. The other 7 pts increased Carbimazole dose to 3 x 3 daily for additional 1 or 2 w. 4 of these 7 pts showed TSH of >30 mIU/L. In 11 pts out of 15 (73.3%) TSH increased to >30 mIU/L and their I-131 WBS showed significant RAIU in residual thyroid tissue/ tumor in the thyroid bed and four of them showed distant metastasis. The mean TSH level before Carbimazole is 9.957±5.9 mIU/L and 25.8± 14.6 mIU/L after Carbimazole with significant statistical difference and P < 0.0001.

Conclusions In thyroid cancer pts with large residual thyroid tissue/tumor or functioning metastasis and low TSH level inspite of thyroxin withdrawal and rhTSH is not available, Carbimazole can be used to enhance TSH level to allow diagnosis and treatment with radioactive iodine.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 55, Issue supplement 1
May 2014
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Management of cancer thyroid: Is there a role for carbimazole?
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Management of cancer thyroid: Is there a role for carbimazole?
Hussein Farghaly, Waleed Diab, Lamia Mahmoud, Hemat Mahmoud, Nahla Bashank, Asmaa Mohamed
Journal of Nuclear Medicine May 2014, 55 (supplement 1) 480;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Management of cancer thyroid: Is there a role for carbimazole?
Hussein Farghaly, Waleed Diab, Lamia Mahmoud, Hemat Mahmoud, Nahla Bashank, Asmaa Mohamed
Journal of Nuclear Medicine May 2014, 55 (supplement 1) 480;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

General Clinical Specialties

  • 18F-FDG PET/CT Imaging of Infection and Inflammation
  • Association between diffuse F18-FDG thyroid uptake and thyroid dysfunction
  • Bone Scintigraphy in Complex Regional Pain Syndrome Type I: A Pictorial Review
Show more General Clinical Specialties

Parathyroid Disease

  • The role of Tc-99m-MIBI SPECT/CT in localization diagnosis of parathyroid adenoma and hyperplasia
  • Clinical impact of SPECT/CT in the surgical treatment of primary hyperparathyroidism
Show more Parathyroid Disease

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire